{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:51:00Z","timestamp":1790884260989,"version":"4.1.0"},"reference-count":26,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Sickle cell disease (SCD) induces a chronic prothrombotic state. Central venous access devices (CVADs) are commonly used for chronic transfusions and iron chelation in this population. CVADs are an additional venous thromboembolism (VTE) risk factor. The role of thromboprophylaxis in this setting is uncertain. The objectives are: (1) to determine whether thromboprophylaxis reduces VTE risk in SCD patients with CVAD and (2) to explore characteristics associated with VTE risk. We identified adults with SCD and CVAD intended for chronic use (\u22653 months) at two comprehensive SCD centers. Thromboprophylaxis presence; type; intensity; and patient-, catheter-, and treatment-related VTE risk factors were recorded. Among 949 patients, 49 had a CVAD (25 without and 24 with VTE prophylaxis). Thromboprophylaxis type and intensity varied widely. Patients without thromboprophylaxis had higher VTE rates (rate ratio (RR) = 4.0 (95% confidence interval: 1.2\u201312.6), p = 0.02). Hydroxyurea was associated with lower VTE rates (RR = 20.5 (6.4\u201365.3), p &lt; 0.001). PICC lines and Vortex and Xcela Power implantable devices were associated with higher rates compared with Port-a-Cath (RR = 5.8 (1.3\u201325.9), p = 0.02, and RR = 58.2 (15.0\u2013225.0), p &lt; 0.001, respectively). Thromboprophylaxis, hydroxyurea, and CVAD subtype were independently associated with VTE. The potentially protective role of thromboprophylaxis and hydroxyurea for VTE prevention in patients with SCD and CVAD merits further exploration.<\/jats:p>","DOI":"10.3390\/jcm11051193","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T22:54:02Z","timestamp":1645656842000},"page":"1193","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-9234","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Fort\u00e9","sequence":"first","affiliation":[{"name":"Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4138-4218","authenticated-orcid":false,"given":"Gonzalo","family":"De Luna","sequence":"additional","affiliation":[{"name":"Sickle Cell Referral Center, Department of Internal Medicine, Henri Mondor University Hospital, UPEC, APHP, 94000 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-2406","authenticated-orcid":false,"given":"Jameel","family":"Abdulrehman","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafanta","family":"Fadiga","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Pestrin","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Pham Hung d\u2019Alexandry d\u2019Orengiani","sequence":"additional","affiliation":[{"name":"Sickle Cell Referral Center, Department of Internal Medicine, Henri Mondor University Hospital, UPEC, APHP, 94000 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Chinawaeze","family":"Aneke","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Guillet","sequence":"additional","affiliation":[{"name":"Sickle Cell Referral Center, Department of Internal Medicine, Henri Mondor University Hospital, UPEC, APHP, 94000 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalton","family":"Budhram","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoosha","family":"Habibi","sequence":"additional","affiliation":[{"name":"Sickle Cell Referral Center, Department of Internal Medicine, Henri Mondor University Hospital, UPEC, APHP, 94000 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4807-8603","authenticated-orcid":false,"given":"Richard","family":"Ward","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7007-1344","authenticated-orcid":false,"given":"Pablo","family":"Bartolucci","sequence":"additional","affiliation":[{"name":"Sickle Cell Referral Center, Department of Internal Medicine, Henri Mondor University Hospital, UPEC, APHP, 94000 Cr\u00e9teil, France"},{"name":"Laboratoire D\u2019Excellence, GRex, Institut Mondor, INSERM U955 Equipe 2, 94000 Cre\u0301teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-9238","authenticated-orcid":false,"given":"Kevin H. M.","family":"Kuo","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/asheducation-2016.1.640","article-title":"Sickle cell disease: An inherited thrombophilia","volume":"2016","author":"Wun","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s11239-013-0895-y","article-title":"Sickle cell disease and venous thromboembolism: What the anticoagulation expert needs to know","volume":"35","author":"Naik","year":"2013","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.3324\/haematol.2019.239350","article-title":"The molecular basis for the prothrombotic state in sickle cell disease","volume":"105","author":"Shet","year":"2020","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.amjmed.2012.12.016","article-title":"Venous thromboembolism in adults with sickle cell disease: A serious and under-recognized complication","volume":"126","author":"Naik","year":"2013","journal-title":"Am. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ajh.25508","article-title":"High incidence of venous thromboembolism recurrence in patients with sickle cell disease","volume":"94","author":"Brunson","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1111\/jth.12744","article-title":"Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease","volume":"12","author":"Naik","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1111\/bjh.16619","article-title":"Catheter associated thromboses in patients with sickle cell anaemia and dual lumen Vortex apheresis ports are common and can be clinically asymptomatic","volume":"189","author":"Brewin","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(12)61726-7","article-title":"The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: A randomised, controlled, multicentre clinical trial","volume":"381","author":"Howard","year":"2013","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Matusiak, K., Fort\u00e9, S., Abdulrehman, J., Verhovsek, M., and Kuo, K.H.M. (2021). Use of Thromboprophylaxis for Central Venous Access Devices in Patients with Sickle Cell Disease: A Survey of Canadian Providers. Blood, 138.","DOI":"10.1182\/blood-2021-145889"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11239-013-0914-z","article-title":"Short-term central venous catheter complications in patients with sickle cell disease who undergo apheresis","volume":"37","author":"Yeral","year":"2014","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/ajh.2830290303","article-title":"Totally implantable intravenous catheters in the management of sickle cell anemia","volume":"29","author":"Phillips","year":"1988","journal-title":"Am. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ajh.10047","article-title":"Central venous catheter complications in sickle cell disease","volume":"69","author":"Jeng","year":"2002","journal-title":"Am. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jiph.2011.10.004","article-title":"Complications of PORT-A-CATH(R) in patients with sickle cell disease","volume":"5","author":"Alkindi","year":"2012","journal-title":"J. Infect. Public Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/pbc.20252","article-title":"Cathlink 20: A subcutaneous implanted central venous access device used in children with sickle cell disease on long-term erythrocytapheresis\u2014A report of low complication rates","volume":"44","author":"Raj","year":"2005","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00043426-199511000-00011","article-title":"Long-term central venous access in patients with sickle cell disease. Incidence of thrombotic and infectious complications","volume":"17","author":"Gauderer","year":"1995","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ajh.22230","article-title":"Complications of implantable venous access devices in patients with sickle cell disease","volume":"87","author":"Shah","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1182\/bloodadvances.2019001384","article-title":"Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease","volume":"4","author":"Srisuwananukorn","year":"2020","journal-title":"Blood Adv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1111\/j.1538-7836.2012.04861.x","article-title":"Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia","volume":"10","author":"Colella","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000362148","article-title":"Hydroxyurea increases plasma concentrations of microparticles and reduces coagulation activation and fibrinolysis in patients with sickle cell anemia","volume":"133","author":"Brunetta","year":"2015","journal-title":"Acta Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/03630269.2020.1869565","article-title":"Venous Thromboembolism in Sickle Cell Disease is Associated with Neutrophilia","volume":"45","author":"Gollamudi","year":"2021","journal-title":"Hemoglobin"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ccr3.1187","article-title":"Catheter-related right atrial thrombus in sickle cell disease","volume":"5","author":"Zhao","year":"2017","journal-title":"Clin. Case Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0002-8703(98)70322-9","article-title":"Right atrial thrombi are related to indwelling central venous catheter position: Insights into time course and possible mechanism of formation","volume":"135","author":"Gilon","year":"1998","journal-title":"Am. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1093\/ndt\/gfr739","article-title":"Right atrial thrombi complicating haemodialysis catheters. A meta-analysis of reported cases and a proposal of a management algorithm","volume":"27","author":"Stavroulopoulos","year":"2012","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/bloodadvances.2019000940","article-title":"Bleeding in patients with sickle cell disease: A population-based study","volume":"4","author":"Hariharan","year":"2020","journal-title":"Blood Adv."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/5\/1193\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:25:55Z","timestamp":1760135155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/5\/1193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["jcm11051193"],"URL":"https:\/\/doi.org\/10.3390\/jcm11051193","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]}}}